|
|
Volumn 13, Issue 4, 2002, Pages 501-502
|
|
Inhibition of bcl-2 as cancer therapy
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTISENSE OLIGONUCLEOTIDE;
CYTOTOXIC AGENT;
DACARBAZINE;
MESSENGER RNA;
OBLIMERSEN;
PACLITAXEL;
PHOSPHOROTHIOIC ACID;
PROTEIN BAD;
PROTEIN BAX;
PROTEIN BCL 2;
PROTEIN BCL XL;
ADVANCED CANCER;
ANIMAL EXPERIMENT;
ANIMAL MODEL;
CLINICAL TRIAL;
COMPLEMENT ACTIVATION;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DRUG MECHANISM;
DRUG POTENTIATION;
DRUG SYNTHESIS;
DRUG TARGETING;
EDITORIAL;
GENE EXPRESSION;
HUMAN;
INFLAMMATION;
LUNG SMALL CELL CANCER;
MELANOMA;
MITOSIS INHIBITION;
MOUSE;
NONHODGKIN LYMPHOMA;
NONHUMAN;
PHASE 1 CLINICAL TRIAL;
PHASE 2 CLINICAL TRIAL;
PHASE 3 CLINICAL TRIAL;
PRIORITY JOURNAL;
PROSTATE CANCER;
RANDOMIZED CONTROLLED TRIAL;
THROMBOCYTOPENIA;
CARCINOMA, SMALL CELL;
CLINICAL TRIALS;
DISEASE PROGRESSION;
GENES, BCL-2;
HUMANS;
LUNG NEOPLASMS;
OLIGONUCLEOTIDES, ANTISENSE;
PROTO-ONCOGENE PROTEINS C-BCL-2;
THIONUCLEOTIDES;
TREATMENT OUTCOME;
|
|
EID: 0036234117
PISSN: 09237534
EISSN: None
Source Type: Journal
DOI: 10.1093/annonc/mdf191 Document Type: Editorial |
|
Times cited : (31)
|
|
References (20)
|
